Suppr超能文献

非小细胞肺癌中上皮内和间质中 CD3、CD117 和 CD138 阳性细胞的预后价值。

The prognostic value of intraepithelial and stromal CD3-, CD117- and CD138-positive cells in non-small cell lung carcinoma.

机构信息

Department of Pathology, Nordland Central Hospital, Bodø, Norway.

出版信息

APMIS. 2010 May;118(5):371-82. doi: 10.1111/j.1600-0463.2010.02609.x.

Abstract

The major value of prognostic markers in potentially curable non-small cell lung carcinoma (NSCLC) should be to guide therapy after surgical treatment. Although tumor-infiltrating T lymphocytes and plasma cells have been documented in NSCLC, a clear association with clinical outcome, especially for the stromal component, has not been well established. The aim of this study was to elucidate the prognostic significance of these cells/markers in the epithelial and stromal compartments of NSCLC. Tissue microarrays from 335 resected, stage I-IIIA, NSCLC were constructed by duplicate cores from viable neoplastic epithelial and stromal areas. Immunohistochemistry was used to evaluate the infiltration of CD3(+), CD117(+) as well as CD138(+) cells in epithelial and stromal areas. In univariate analyses, increasing numbers of stromal CD3(+) (p = 0.001) and epithelial CD3(+) cells (p = 0.004) correlated significantly with an improved disease-specific survival. No such relation was noted with CD3(+) or CD117(+) cells. In the multivariate analysis, stromal CD3(+) cells was an independent prognostic factor for disease-specific survival (HR 1.925, CI 1.21-3.04, p = 0.005). Increased presence of the pan T-cell marker, CD3, which is an independent factor, correlates with improved clinical outcome in NSCLC. This prognostic impact of T cells is clearer in the tumor stroma. Neither plasma cells nor mast cells were prognostic indicators in our cohort.

摘要

在有治愈可能的非小细胞肺癌(NSCLC)中,预后标志物的主要价值应该是指导手术治疗后的治疗。尽管已经在 NSCLC 中记录了肿瘤浸润性 T 淋巴细胞和浆细胞,但尚未明确其与临床结果的关联,尤其是对基质成分。本研究的目的是阐明这些细胞/标志物在 NSCLC 的上皮和基质区室中的预后意义。通过从存活的肿瘤上皮和基质区域的重复核心构建了 335 个切除的 I 期-IIIA 期 NSCLC 的组织微阵列。免疫组织化学用于评估上皮和基质区室中 CD3(+)、CD117(+)和 CD138(+)细胞的浸润。在单因素分析中,基质 CD3(+)(p = 0.001)和上皮 CD3(+)细胞(p = 0.004)数量的增加与疾病特异性生存率的提高显著相关。未注意到与 CD3(+)或 CD117(+)细胞相关的关系。在多因素分析中,基质 CD3(+)细胞是疾病特异性生存的独立预后因素(HR 1.925,CI 1.21-3.04,p = 0.005)。泛 T 细胞标志物 CD3 的存在增加,这是一个独立的因素,与 NSCLC 的临床结果改善相关。这种 T 细胞的预后影响在肿瘤基质中更为明显。在我们的队列中,浆细胞和肥大细胞都不是预后指标。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验